References
- Gladman M, DeHaan M, Pinto H, Geerts W, Zinman L. Venous thromboembolism in amyotrophic lateral sclerosis. A prospective study. Neurology. 2014;82:1674–17.
- Berry JD, Korngut L. Re-evaluating the risk of DVT in people with ALS weak in the knees and DVTs. Neurology. 2014;82:1668–9.
- Kahn SR, Lim W, Dunn AS, Cushman M, Dentali F, Akl EA, et el. Prevention of VTE in Nonsurgical Patients: Antithrombotic Therapy and Prevention of Thrombosis, 9th edn: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. CHEST. 2012; 141(Suppl):eS195–226.
- Alikhan R, Bedenis R, Cohen AT. Heparin for the prevention of venous thromboembolism in acutely ill medical patients (excluding stroke and myocardial infarction). Cochrane Database Syst Rev.2014 May 7;5:CD003747.
- Cohen AT, Davidson BL, Gallus AS, Lassen MR, Prins MH, Tomkowski W, et al. Efficacy and safety of fondaparinux for the prevention of venous thromboembolism in older acute medical patients: Randomized placebo controlled trial. Br Med J. 2006;332:325–7.
- Cohen AT, Spiro TE, Büller HR, Haskell L, Hu D, Hull R, et al. Rivaroxaban for Thromboprophylaxis in Acutely Ill Medical Patients. N Engl J Med. 2013;368: 513–23.